Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Bioimpedance Spectroscopy May Better Identify Lymphedema Progression

Publish date:: June 27, 2019

Key clinical point: Bioimpedance spectroscopy may better identify lymphedema progression in women at risk for breast cancer–related lymphedema over the traditionally used method of monitoring arm circumference with a tape measure.

Major finding: In the bioimpedance spectroscopy group, there was a 10% absolute reduction and 67% relative reduction in lymphedema progression.

Study details: Interim analysis from the PREVENT trial.

Disclosures: The study was funded by ImpediMed. Dr. Ridner reports being the principal investigator for ImpediMed and Tactile Medical through work agreements contracted between the companies and her institution.

Citation:

REPORTING FROM ASBS 2019

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in Breast Cancer

Increased Cancer Death Linked to Radioactive Iodine Therapy,

Bioimpedance Spectroscopy May Better Identify Lymphedema Progression,

Stereotactic Radiotherapy System Approved For BC, FDA news release; 2017 Dec 22

Perjeta Approved for Certain Type of Early BC, Genentech news release; 2017 Dec 20

Cochrane on Bisphosphonates for Breast Cancer, Cochrane; 2017 Oct 30; O'Carrigan, Wong, et al